Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence
Open Access
- 13 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
The main challenge in the treatment of acute myeloid leukemia (AML) is relapse, as it has no good treatment options and 90% of relapsed patients die as a result. It is now well accepted that relapse is due to a persisting subset of AML cells known as leukemia-initiating cells or leukemic stem cells (LSCs). Hematopoietic stem cells (HSCs) reside in the bone marrow microenvironment (BMM), a specialized niche that coordinates HSC self-renewal, proliferation, and differentiation. HSCs are divided into two types: long-term HSCs (LT-HSCs) and short-term HSCs, where LT-HSCs are typically quiescent and act as a reserve of HSCs. Like LT-HSCs, a quiescent population of LSCs also exist. Like LT-HSCs, quiescent LSCs have low metabolic activity and receive pro-survival signals from the BMM, making them resistant to drugs, and upon discontinuation of therapy, they can become activated and re-establish the disease. Several studies have shown that the activation of quiescent LSCs may sensitize them to cytotoxic drugs. However, it is very difficult to experimentally model the quiescence-inducing BMM. Here we report that culturing AML cells with bone marrow stromal cells, transforming growth factor beta-1 and hypoxia in a three-dimensional system can replicate the quiescence-driving BMM. A quiescent-like state of the AML cells was confirmed by reduced cell proliferation, increased percentage of cells in the G0 cell cycle phase and a decrease in absolute cell numbers, expression of markers of quiescence, and reduced metabolic activity. Furthermore, the culture could be established as co-axial microbeads, enabling high-throughput screening, which has been used to identify combination drug treatments that could break BMM-mediated LSC quiescence, enabling the eradication of quiescent LSCs.Funding Information
- Horizon 2020 (777995)
- Science Foundation Ireland (SFI/TIDA/B2388)
- Irish Cancer Society (BCNI/ICS/B3042)
- Irish Research Council
- National University of Ireland, Galway
- National University of Ireland, Galway
This publication has 43 references indexed in Scilit:
- The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem CellsAdvances in Hematology, 2013
- CDK4: A Key Player in the Cell Cycle, Development, and CancerGenes & Cancer, 2012
- Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinationsBritish Journal of Cancer, 2012
- Biology of cancerMedicine, 2011
- Oncogenes and Tumor Suppressor GenesCold Spring Harbor Perspectives in Biology, 2010
- Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AMLNature Biotechnology, 2010
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- IFNα activates dormant haematopoietic stem cells in vivoNature, 2009
- Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cellsNature, 2009
- Cellular quiescence induced by contact inhibition or serum withdrawal in C3H10T1/2 cellsCell Proliferation, 2005